Dyne Therapeutics Reports Third Quarter 2026 Financial Results and Recent Business HighlightsGlobeNewsWire • 1h
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire • 10/22/26
Dyne: Recent Price Drop On Rival's DM1 Data Creates (Risky) 'Buy The Dip' ScenarioSeeking Alpha • 09/30/26
Dyne Therapeutics Announces Additional One-Year Clinical Data from Phase 1/2 ACHIEVE Trial of Z-Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1)GlobeNewsWire • 09/29/26
Dyne Therapeutics, Inc. (DYN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeeking Alpha • 09/14/26
Dyne Therapeutics Remains A Buy Even As Novartis Trial Failure Hits DM1 ClassSeeking Alpha • 09/09/26
Dyne, Sarepta shares tumble as Novartis setback weighs on muscle disease drug developersReuters • 09/08/26
Dyne Therapeutics to Present Additional One-Year Clinical Data from Phase 1/2 ACHIEVE Trial of Z-Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1) at Upcoming Medical MeetingsGlobeNewsWire • 09/08/26
Dyne Therapeutics to Present Preclinical Data for Multiple Development Candidates for Duchenne Muscular Dystrophy (DMD) at 27th Annual NMSG Scientific MeetingGlobeNewsWire • 09/03/26
Dyne Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business HighlightsGlobeNewsWire • 07/29/26
Dyne Therapeutics Announces U.S. FDA Clearance of Investigational New Drug (IND) Application for DYNE-302 in Facioscapulohumeral Muscular Dystrophy (FSHD)GlobeNewsWire • 07/28/26
Dyne Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional SharesGlobeNewsWire • 07/23/26
Dyne Therapeutics Announces Pricing of Upsized $375 Million Public Offering of Common StockGlobeNewsWire • 07/22/26
Dyne Therapeutics Trades Sideways Over An FDA Hurdle. Is It Time To Take Profits?Investors Business Daily • 07/20/26
Dyne Therapeutics Announces U.S. FDA Acceptance of Biologics License Application (BLA) for Z-Rostudirsen in Exon 51 Duchenne Muscular Dystrophy (DMD)GlobeNewsWire • 07/20/26
Dyne Therapeutics vs. Recursion Pharmaceuticals: Which Development Stage Pharma Stock Is a Better Buy in 2026?The Motley Fool • 07/04/26
Dyne Therapeutics vs. Vertex Pharmaceuticals: Which Drug Innovator Stock Is a Better Buy in 2026?The Motley Fool • 07/01/26
Dyne Therapeutics vs. Viking Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?The Motley Fool • 06/26/26